[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:osteosarcoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":314,"states":315},"Osteosarcoma",67,64,[8,16,23,30,36,42,48,54,60,66,72,78,84,91,97,104,110,116,122,128,134,140,146,152,158,164,170,176,182,187,193,199,205,211,217,223,229,235,241,247,253,259,265,271,277,284,290,296,302,308],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06892678","DFMO Maintenance for Patients With Relapsed\u002FRefractory Ewing Sarcoma or Osteosarcoma",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:18:30.351130Z","2026-07-05T05:32:16.700101Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05726383","Iscador® P (Mistletoe) Immunotherapy for Recurrent Osteogenic Sarcoma",[20],"Phase 2","2026-08-26T02:15:28.524219Z","2026-05-05T02:43:29.698149Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06492954","Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma",[27],"Phase 1","2026-08-26T02:17:17.791881Z","2026-05-05T02:43:29.340134Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT07227571","Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent\u002FProgressive Osteosarcoma, FIERCe Trial",[27],"2026-08-26T02:15:01.639696Z","2026-05-05T02:43:29.202539Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT05588648","Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma",[12],"2026-08-26T02:17:26.640202Z","2026-05-05T02:43:28.871840Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT03900793","Losartan + Sunitinib in Treatment of Osteosarcoma",[27],"2026-08-26T02:16:54.876240Z","2026-05-05T02:43:28.486733Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT07477457","A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma",[20],"2026-08-26T02:18:58.958025Z","2026-05-05T02:43:28.368891Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT07144254","Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma",[27],"2026-08-26T02:16:27.227548Z","2026-05-05T02:43:28.126788Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT03721068","Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed\u002FRefractory Neuroblastoma or Relapsed\u002FRefractory Osteosarcoma",[27],"2026-08-26T02:19:19.162260Z","2026-05-05T02:43:28.120445Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT07211737","NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma",[27],"2026-08-26T02:19:23.493898Z","2026-05-05T02:43:27.839814Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT05400603","Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed \u002FRefractory Neuroblastoma or Refractory\u002F Relapsed Osteosarcoma",[27],"2026-08-26T02:15:38.131683Z","2026-05-05T02:43:27.744003Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT07428993","Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma",[20],"2026-08-26T02:15:57.572488Z","2026-05-05T02:43:27.043487Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":89,"content_modified":90},"NCT05691478","A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma",[88],"Phase 2\u002FPhase 3","2026-08-03T02:24:39.214133Z","2026-05-05T02:43:26.755943Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT07357519","Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)",[12],"2026-08-26T02:18:51.009190Z","2026-05-05T02:43:26.711992Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":102,"content_modified":103},"NCT05235165","Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma",[101],"Phase 3","2026-08-26T02:17:24.721169Z","2026-05-05T02:35:31.613742Z",{"nct_id":105,"title":106,"phases":107,"status":13,"updated_at":108,"content_modified":109},"NCT05019703","Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study",[20],"2026-08-26T02:18:58.141497Z","2026-04-29T02:57:57.175971Z",{"nct_id":111,"title":112,"phases":113,"status":13,"updated_at":114,"content_modified":115},"NCT07321912","Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma",[20],"2026-08-26T02:17:22.949982Z","2026-05-29T15:36:40.187051Z",{"nct_id":117,"title":118,"phases":119,"status":13,"updated_at":120,"content_modified":121},"NCT05621668","A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced\u002FMetastatic Soft Tissue and Bone Sarcoma",[27],"2026-08-03T02:56:00.496454Z","2026-05-05T02:43:29.232388Z",{"nct_id":123,"title":124,"phases":125,"status":13,"updated_at":126,"content_modified":127},"NCT03965234","Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases",[12],"2026-08-26T02:17:39.857430Z","2026-05-05T02:43:29.135284Z",{"nct_id":129,"title":130,"phases":131,"status":13,"updated_at":132,"content_modified":133},"NCT07193550","A Phase 2 Trial of Zanzalintinib in Advanced\u002FMetastatic Bone Sarcomas (ZAMBONE)",[20],"2026-08-26T02:16:35.654046Z","2026-05-05T02:43:28.850363Z",{"nct_id":135,"title":136,"phases":137,"status":13,"updated_at":138,"content_modified":139},"NCT06156410","Cabozantinib With Ifosfamide in Relapsed\u002FRefractory Sarcomas",[27],"2026-08-26T02:17:18.747857Z","2026-05-05T02:43:28.669008Z",{"nct_id":141,"title":142,"phases":143,"status":13,"updated_at":144,"content_modified":145},"NCT04040205","Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration",[20],"2026-08-26T02:18:07.037408Z","2026-05-05T02:43:28.417090Z",{"nct_id":147,"title":148,"phases":149,"status":13,"updated_at":150,"content_modified":151},"NCT05210374","Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas",[27],"2026-08-26T02:15:20.225313Z","2026-05-05T02:43:27.805890Z",{"nct_id":153,"title":154,"phases":155,"status":13,"updated_at":156,"content_modified":157},"NCT05634369","A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue",[12],"2026-08-26T02:17:41.695983Z","2026-05-05T02:35:31.762190Z",{"nct_id":159,"title":160,"phases":161,"status":13,"updated_at":162,"content_modified":163},"NCT06571734","XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma",[20],"2026-08-26T02:17:14.343713Z","2026-07-05T05:32:16.766529Z",{"nct_id":165,"title":166,"phases":167,"status":13,"updated_at":168,"content_modified":169},"NCT06625190","Alpha\u002FBeta T and B Cell Depletion With Zoledronic Acid for Solid Tumors",[12],"2026-08-26T02:19:04.543908Z","2026-07-05T03:45:20.453806Z",{"nct_id":171,"title":172,"phases":173,"status":13,"updated_at":174,"content_modified":175},"NCT06541262","Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors",[12],"2026-08-26T02:16:21.385056Z","2026-07-05T03:45:20.453347Z",{"nct_id":177,"title":178,"phases":179,"status":13,"updated_at":180,"content_modified":181},"NCT06465199","Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas",[12],"2026-08-26T02:15:58.452248Z","2026-06-16T05:54:07.918391Z",{"nct_id":183,"title":184,"phases":185,"status":13,"updated_at":40,"content_modified":186},"NCT02508038","Alpha\u002FBeta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors",[27],"2026-05-05T02:43:29.192915Z",{"nct_id":188,"title":189,"phases":190,"status":13,"updated_at":191,"content_modified":192},"NCT04851119","Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors",[12],"2026-08-26T02:16:41.943926Z","2026-05-05T02:43:29.139986Z",{"nct_id":194,"title":195,"phases":196,"status":13,"updated_at":197,"content_modified":198},"NCT05135975","A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors",[20],"2026-08-26T02:16:46.147215Z","2026-05-05T02:43:28.530799Z",{"nct_id":200,"title":201,"phases":202,"status":13,"updated_at":203,"content_modified":204},"NCT04897321","B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)",[27],"2026-08-26T02:16:45.157238Z","2026-05-05T02:43:28.511090Z",{"nct_id":206,"title":207,"phases":208,"status":13,"updated_at":209,"content_modified":210},"NCT06500819","Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed\u002FRefractory Solid Tumors",[27],"2026-08-26T02:18:39.640967Z","2026-05-05T02:43:28.289390Z",{"nct_id":212,"title":213,"phases":214,"status":13,"updated_at":215,"content_modified":216},"NCT04995003","HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma",[27],"2026-08-26T02:16:31.714843Z","2026-05-05T02:43:27.987147Z",{"nct_id":218,"title":219,"phases":220,"status":13,"updated_at":221,"content_modified":222},"NCT05238792","Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors",[27],"2026-08-26T02:19:28.327680Z","2026-05-05T02:43:27.959678Z",{"nct_id":224,"title":225,"phases":226,"status":13,"updated_at":227,"content_modified":228},"NCT01804634","Reduced Intensity Haploidentical BMT for High Risk Solid Tumors",[20],"2026-08-26T02:15:50.539717Z","2026-05-05T02:43:27.448232Z",{"nct_id":230,"title":231,"phases":232,"status":13,"updated_at":233,"content_modified":234},"NCT07222735","Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed\u002FRefractory Sarcomas",[27],"2026-08-26T02:17:48.768272Z","2026-05-05T02:43:27.273704Z",{"nct_id":236,"title":237,"phases":238,"status":13,"updated_at":239,"content_modified":240},"NCT05253131","Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas",[20],"2026-08-26T02:15:37.042762Z","2026-05-05T02:43:27.251035Z",{"nct_id":242,"title":243,"phases":244,"status":13,"updated_at":245,"content_modified":246},"NCT06709495","Phase 1\u002F2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas",[12],"2026-08-26T02:16:24.135291Z","2026-05-05T02:43:27.245630Z",{"nct_id":248,"title":249,"phases":250,"status":13,"updated_at":251,"content_modified":252},"NCT04469530","Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors",[20],"2026-08-26T02:18:49.989941Z","2026-05-05T02:43:27.107017Z",{"nct_id":254,"title":255,"phases":256,"status":13,"updated_at":257,"content_modified":258},"NCT04282044","Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies",[27],"2026-08-26T02:16:05.813655Z","2026-05-05T02:43:26.932270Z",{"nct_id":260,"title":261,"phases":262,"status":13,"updated_at":263,"content_modified":264},"NCT05227326","AOH1996 for the Treatment of Refractory Solid Tumors",[27],"2026-08-26T02:19:20.945539Z","2026-05-05T02:43:26.920202Z",{"nct_id":266,"title":267,"phases":268,"status":13,"updated_at":269,"content_modified":270},"NCT05642455","SPEARHEAD-3 Pediatric Study",[12],"2026-08-26T02:15:11.740957Z","2026-05-05T02:43:26.852369Z",{"nct_id":272,"title":273,"phases":274,"status":13,"updated_at":275,"content_modified":276},"NCT04901702","Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma",[12],"2026-08-26T02:18:32.765187Z","2026-05-05T02:35:31.688370Z",{"nct_id":278,"title":279,"phases":280,"status":13,"updated_at":282,"content_modified":283},"NCT02446431","Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence",[281],"Early Phase 1","2026-08-26T02:16:12.203827Z","2026-05-05T02:43:28.295351Z",{"nct_id":285,"title":286,"phases":287,"status":13,"updated_at":288,"content_modified":289},"NCT04199741","PET\u002FCT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56",[12],"2026-08-26T02:18:04.640417Z","2026-07-05T05:32:16.773657Z",{"nct_id":291,"title":292,"phases":293,"status":13,"updated_at":294,"content_modified":295},"NCT06387485","A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning",[],"2026-08-26T02:18:34.622081Z","2026-05-05T02:43:28.883449Z",{"nct_id":297,"title":298,"phases":299,"status":13,"updated_at":300,"content_modified":301},"NCT04084067","Indocyanine Green (ICG) Guided Tumor Resection",[27],"2026-08-26T02:19:10.436356Z","2026-05-05T02:43:28.715739Z",{"nct_id":303,"title":304,"phases":305,"status":13,"updated_at":306,"content_modified":307},"NCT06235125","Safety and Feasibility of Intraoperative Visualization With Cytalux in Children",[27],"2026-08-26T02:16:02.918558Z","2026-05-05T02:43:27.069602Z",{"nct_id":309,"title":310,"phases":311,"status":13,"updated_at":312,"content_modified":313},"NCT07725380","Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma",[12],"2026-08-26T02:17:51.502023Z","2026-07-30T01:46:14.448336Z",[],[316,320,324,328,332,336,339,342,346,350,353,357,361,365,368,371,374,377,381,384,387,391,394,397],{"state":317,"count":318,"slug":319},"California",21,"california",{"state":321,"count":322,"slug":323},"Texas",19,"texas",{"state":325,"count":326,"slug":327},"New York",18,"new-york",{"state":329,"count":330,"slug":331},"Tennessee",15,"tennessee",{"state":333,"count":334,"slug":335},"Florida",14,"florida",{"state":337,"count":334,"slug":338},"Ohio","ohio",{"state":340,"count":334,"slug":341},"Pennsylvania","pennsylvania",{"state":343,"count":344,"slug":345},"Georgia",13,"georgia",{"state":347,"count":348,"slug":349},"Massachusetts",12,"massachusetts",{"state":351,"count":348,"slug":352},"Missouri","missouri",{"state":354,"count":355,"slug":356},"Alabama",10,"alabama",{"state":358,"count":359,"slug":360},"New Jersey",9,"new-jersey",{"state":362,"count":363,"slug":364},"Arizona",8,"arizona",{"state":366,"count":363,"slug":367},"Colorado","colorado",{"state":369,"count":363,"slug":370},"Illinois","illinois",{"state":372,"count":363,"slug":373},"North Carolina","north-carolina",{"state":375,"count":363,"slug":376},"Utah","utah",{"state":378,"count":379,"slug":380},"District of Columbia",7,"district-of-columbia",{"state":382,"count":379,"slug":383},"Minnesota","minnesota",{"state":385,"count":379,"slug":386},"Washington","washington",{"state":388,"count":389,"slug":390},"Maryland",6,"maryland",{"state":392,"count":389,"slug":393},"Michigan","michigan",{"state":395,"count":389,"slug":396},"Wisconsin","wisconsin",{"state":398,"count":399,"slug":400},"Arkansas",5,"arkansas"]